[
    [
        {
            "time": "",
            "original_text": "机构最新持股名单曝光！社保基金、外资提前布局多只牛股，他们手里还持有这些个股（附名单）",
            "features": {
                "keywords": [
                    "机构持股",
                    "社保基金",
                    "外资",
                    "牛股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "机构最新持股名单曝光！社保基金、外资提前布局多只牛股，他们手里还持有这些个股（附名单）",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药获仿制药一致性评价 却难言丰厚利润空间",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "仿制药",
                    "一致性评价",
                    "利润空间"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药获仿制药一致性评价 却难言丰厚利润空间",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "上市公司现金红包雨逐年加大 23家公司股息率超3%",
            "features": {
                "keywords": [
                    "上市公司",
                    "现金分红",
                    "股息率"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上市公司现金红包雨逐年加大 23家公司股息率超3%",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "全球“药王”内地遇冷还遭扎堆仿制 抗癌药新贵PD-1被围剿",
            "features": {
                "keywords": [
                    "药王",
                    "仿制",
                    "抗癌药",
                    "PD-1"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "全球“药王”内地遇冷还遭扎堆仿制 抗癌药新贵PD-1被围剿",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "年销售额达3.5亿的替吉奥 齐鲁、恒瑞已过评",
            "features": {
                "keywords": [
                    "替吉奥",
                    "齐鲁",
                    "恒瑞",
                    "一致性评价"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "年销售额达3.5亿的替吉奥 齐鲁、恒瑞已过评",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "孔明直播：《3月13日热点信息+个股公告》",
            "features": {
                "keywords": [
                    "孔明直播",
                    "热点信息",
                    "个股公告"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "孔明直播：《3月13日热点信息+个股公告》",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "13日最新公告透露利好 16只个股有潜力",
            "features": {
                "keywords": [
                    "公告",
                    "利好",
                    "个股潜力"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "13日最新公告透露利好 16只个股有潜力",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "迈博药业“零主营业务收入”冲港股，核心药品研发16年仍未结果",
            "features": {
                "keywords": [
                    "迈博药业",
                    "港股",
                    "药品研发"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "迈博药业“零主营业务收入”冲港股，核心药品研发16年仍未结果",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "北上资金恢复净买入 持续调仓金融和消费板块",
            "features": {
                "keywords": [
                    "北上资金",
                    "净买入",
                    "金融",
                    "消费"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北上资金恢复净买入 持续调仓金融和消费板块",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "3000点争夺战机构观点现分歧 紧盯券商最新动向寻“钱途”",
            "features": {
                "keywords": [
                    "3000点",
                    "机构观点",
                    "券商",
                    "钱途"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "3000点争夺战机构观点现分歧 紧盯券商最新动向寻“钱途”",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]